Profound Medical (PROF) vs RxSight (RXST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Profound Medical (PROF) has outperformed RxSight (RXST) over the past year, losing 12.1% versus a loss of 42.0%. Over five years, PROF leads with a -62.2% price change compared with -64.6% for RXST. Profound Medical is the larger company by market cap ($240.1 million vs $199.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROF | RXST |
|---|---|---|
| Share price | $6.57 | $4.80 |
| Market cap | $240.07M | $199.65M |
| 1-day change | +15.67% | 0.00% |
| YTD return | -27.83% | -53.93% |
| 1-year return | -12.07% | -42.03% |
| 5-year return | -62.16% | -64.60% |
| EPS (TTM) | $-0.99 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.95 | $13.22 |
| 52-week low | $4.80 | $4.48 |
| Distance from 52-week high | -26.59% | -63.69% |
| Analyst consensus | none | none |
| Avg. price target upside | +69.56% | +57.71% |
| Average volume | 124.80K | 861.57K |
| Shares outstanding | 36.54M | 41.59M |
| Employees | 162 | 461 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PROF has outperformed RXST by 30.0 percentage points over the past year.
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Health Care · Medical/Dental Instruments · 162 employees
About RxSight
RXST stock →RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Health Care · Ophthalmic Goods · 461 employees
PROF vs RXST FAQ
Which is bigger, Profound Medical or RxSight?
Profound Medical (PROF) is larger, with a market capitalization of $240.07M compared with $199.65M for RxSight (RXST).
Which stock has performed better over the past year, PROF or RXST?
PROF returned -12.07% over the past 12 months, compared with -42.03% for RXST (price return, excluding dividends). Past performance does not predict future results.
Are Profound Medical and RxSight in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Profound Medical and Ophthalmic Goods for RxSight.